What is Vemurafenib?

Vemurafenib (Vemurafenib) is approved by the U.S. Food and Drug Administration (FDA) for V600-mutated metastatic and unresectable melanoma and Erdheim-Chester disease (non-Langerhans histiocytosis). Non-FDA labeled indications include metastatic and unresectable BRAF V600K melanoma and refractory non-small cell lung cancer with BRAF V600 mutations.

Before starting treatment, patients must confirm the presence of BRAF V600E mutation The physician will obtain an electrocardiogram and serum electrolyte concentrations (i.e., potassium, magnesium, calcium) and will evaluate liver enzyme and bilirubin concentrations, baseline Scr concentrations, and dermatology. Advise patients to avoid sun exposure. The BRIM II trial determined that the effective non-toxic dose of vemurafenib was 960 mg taken twice daily. When taken orally, the drug reaches peak plasma concentrations within 3 hours. The half-life is between 30-120 hours and reaches plasma steady state in 15-22 days. The drug is started twice daily with 12 hours between doses and should be discontinued if melanoma progression or high toxicity occurs.

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.